Sharekhan has given Buy recommendation for Torrent Pharmaceuticals with a target price of Rs. 3400 in its research report issued on Jul 27, 2021
Sharekhan’s research report on Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited reported steady numbers for Q1FY22, though PAT missed estimates due to a higher tax rate. The company derives ~60% of its sales collectively from the Indian and Brazil markets and the management sees these two geographies as key growth drivers. The Dahej and Indrad plants are under the USFDA’s scrutiny and post clearance, the company looks to launch 12-15 new products annually from the plants.
Given the strong growth outlook across Indian and Brazilian business, we retain a Buy recommendation on the stock with an unchanged PT of Rs 3,400.